Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Medivir AB    MVIR B   SE0000273294

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Medivir AB : Medivir: Simeprevir data from COSMOS study in Hepatitis C patients will be presented as late-breaking presentation at AASLD

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/07/2013 | 02:53pm CEST

Regulatory News:

Medivir AB (OMX: MVIR) announced that data from the phase IIa COSMOS study (Combination Of SiMeprevir and sOfosbuvir in HCV genotype 1 infected patientS) of the investigational protease inhibitor simeprevir (TMC435) administered once daily with Gilead's investigational nucleotide inhibitor sofosbuvir (GS-7977), with and without ribavirin, in genotype 1 chronic hepatitis C adult patients with compensated liver disease has been accepted as a late-breaking oral presentation at the upcoming Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). AASLD will take place November 1 to 5 in Washington, D.C.

The COSMOS data will be presented during the late-breaking oral session on Monday, November 4, 2:45-4:30 p.m. (EST) in Hall E: SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study.

· Lead Author: Ira M. Jacobson, Weill Cornell Medical College, New York, USA

Full session details and data presentation listings for the 2013 AASLD Annual Meeting can be found at http://www.aasld.org/livermeeting.

About Simeprevir

Simeprevir is an investigational NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB, for the treatment of genotype 1 and genotype 4 chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis. Simeprevir works by blocking the protease enzyme that enables the hepatitis C virus to replicate in host cells.

Janssen is responsible for the global clinical development of simeprevir and has acquired exclusive, worldwide marketing rights, except for in the Nordic countries. Medivir will retain marketing rights for simeprevir in these countries.

Simeprevir was approved in Japan in September 2013 for the treatment of genotype 1 hepatitis C. In the U.S., the New Drug Application (NDA) filed by Janssen for simeprevir administered once daily in combination with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients was granted Priority Review designation by the Food and Drug Administration (FDA) in May. A Marketing Authorisation Application was submitted to the European Medicines Agency (EMA) in April seeking approval of simeprevir for the treatment of genotype 1 or genotype 4 chronic hepatitis C.

To date, more than 3,700 patients have been treated with simeprevir in clinical trials. Simeprevir is also being studied in several interferon-free regimens using selected combinations of direct-acting antiviral agents with different mechanisms of action.

For additional information about simeprevir clinical trials, please visit www.clinicaltrials.gov.

About Sofosbuvir

Sofosbuvir (formerly referred to as GS-7977) is a once-daily nucleotide analog polymerase inhibitor for the treatment of HCV infection being developed by Gilead Sciences, Inc. Sofosbuvir is being evaluated as part of multiple therapeutic regimens, including programs with RBV alone and in combination with peg-IFN and RBV.

About Medivir

Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company's key pipeline asset is simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is being developed in collaboration with Janssen R&D Ireland. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.

For more information about Medivir AB, please visit the Company's website: www.medivir.com

This information was brought to you by Cision http://news.cision.com

For more information please contact:
Rein Piir, EVP Corporate Affairs & IR Mobile:
+46 708 537 292.


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDIVIR AB
08/16 MEDIVIR : FDA accepts Medivir's IND application for MIV-711, enabling clinical d..
08/10 MEDIVIR : Recent Findings from Medivir AB Has Provided New Information about Vir..
07/27 MEDIVIR : Patent Issued for Respiratory Syncytial Virus Inhibitors (USPTO 970833..
07/25 MEDIVIR : Interim report, january - june 2017
06/19 MEDIVIR : appoints John Öhd as Chief Medical Officer
06/09 MEDIVIR : Enrolment completed in the MIV-711 osteoarthritis extension study and ..
05/30 MEDIVIR : CFO will leave his position - successor recruitment underway
05/25 MEDIVIR : Patent Issued for Form 2 Crystalline Polymorph of a Salt of N-pyrrole-..
05/03 MEDIVIR : Resolutions at the Annual General Meeting in Medivir on 3 May 2017
04/28 MEDIVIR : Interim report, january - march 2017
More news
News from SeekingAlpha
08/16 Medivir on go to start U.S. clinical development of osteoarthritis candidate ..
07/25 Medivir ABB reports 1H results
05/30 Medivir finance chief to depart in August
04/28 Medivir ABB reports Q1 results
04/11 3 THINGS IN BIOTECH YOU SHOULD LEARN : April 11, 2017
Financials ( SEK)
Sales 2017 66,0 M
EBIT 2017 -295 M
Net income 2017 -286 M
Finance 2017 502 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 13,6x
EV / Sales 2018 0
Capitalization 1 399 M
Chart MEDIVIR AB
Duration : Period :
Medivir AB Technical Analysis Chart | MVIR B | SE0000273294 | 4-Traders
Technical analysis trends MEDIVIR AB
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 1
Average target price 69,0  SEK
Spread / Average Target -2,1%
EPS Revisions
Managers
NameTitle
Christine Lind Chief Executive Officer
Anna Yvonne Monica Malm Bernsten Chairman
Ola Burmark Chief Financial Officer & Head-Investor Relations
John Öhd Chief Medical Officer
Daniel Eriksson Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
MEDIVIR AB-29.08%173
AMGEN16.30%125 059
CELGENE CORPORATION13.40%102 691
GILEAD SCIENCES2.43%95 790
REGENERON PHARMACEUTICALS28.73%50 205
VERTEX PHARMACEUTICALS107.30%38 163